EUCTR2005-000657-29-IT进行中（未招募）不适用
A randomized open label study of 400 mg versus 800 mg of Gleevec/glivec (imatinib mesylate) in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 420
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Ability to provide written informed consent prior to participation to the study. 2. Male or female patients ≥ 18 and ≤ 75 years of age 3. Patients with CML-CP within 6 months of diagnosis (date of initial diagnosis is the date of first cytogenetic analysis). Standard conventional cytogenetic analysis must be done on bone marrow and be of satisfactory quality as outlined in Section 3.5.2.2 (Bone marrow analysis and cytogenetics). FISH analysis will not be accepted. 4. Diagnosis of chronic myelogenous leukemia in chronic phase with cytogenetic confirmation of Philadelphia chromosome of (9;22) translocations and presence of Bcr- Abl 5. Documented chronic phase CML as defined by: ? < 15% blasts in peripheral blood and bone marrow ? < 30% blasts plus promyelocytes in peripheral blood and bone marrow ? < 20% basophils in the peripheral blood ? ≥ 100 x 109/L (≥ 100,000 /mm3) platelets ? No evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly 6. Adequate end organ function as defined by: ? total bilirubin < 1.5 x ULN ? SGOT and SGPT < 2.5 x ULN ? creatinine < 1.5 x ULN 7. Female patients of childbearing potential must have a negative serum pregnancy test within 7 days before initiation of study drug.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients in late chronic phase (i.e., chronic phase diagnosed greater than 6 months ago), accelerated phase, or blastic phase are excluded 2. Patients who have received other investigational agents 3. Treatment with tyrosine kinase inhibitor(s) prior to study entry is not allowed, except with any dose of Gleevec/Glivec for up to 2 weeks prior to study entry. 4. Patient received any treatment for CML prior to study entry for longer than 2 weeks with the exception of hydroxyurea and/or anagrelide 5. Patients with another primary malignancy except if the other primary malignancy is neither currently clinically significant or requiring active intervention 6. Patients who are: (a) pregnant, (b) breast feeding, (c) of childbearing potential without a negative pregnancy test prior to baseline and (d) male or female of childbearing potential unwilling to use contraceptive precautions throughout the trial (post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential). 7. Patient with a severe or uncontrolled medical condition (i.e., uncontrolled diabetes, chronic renal disease) 8. Patient previously received radiotherapy to ≥ 25% of the bone marrow 9. Patient had major surgery within 4 weeks prior to study entry, or who have not recovered from prior major surgery 10. Patients with an ECOG Performance Status Score ≥ 3 11. Patients with International normalized ratio (INR) or partial thromboplastin time (PTT) > 1.5 x ULN, with the exception of patients on treatment with oral anticoagulants 12. Patients with known positivity for human immunodeficiency virus (HIV); baseline testing for HIV is not required 13. Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent 14. Patients with identified sibling donors where allogeneic bone marrow transplant is elected as first line treatment
研究者
相似试验
进行中（未招募）
不适用
A randomized open-label study of 400 mg versus 800 mg of Gleevec/Glivec (imatinib mesylate) in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpointsEstudio abierto, aleatorizado de Glivec (mesilato de imatinib) 400 mg frente a 800 mg en pacientes con leucemia mieloide crónica (LCM-FC), recien diagnosticada y no tratada previamente, utilizando variables molecularesewly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP)EUCTR2005-000657-29-ESovartis Farmacéutica, S.A.420
进行中（未招募）
不适用
A randomized open-label study of 400 mg versus 800 mg of Gleevec/Glivec (imatinib mesylate) in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints - N/Aewly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP)EUCTR2005-000657-29-CZovartis Pharma Services AG420
进行中（未招募）
1 期
A randomized open-label study of 400 mg versus 800 mg of Gleevec/Glivec (imatinib mesylate) in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints - N/AEUCTR2005-000657-29-SKovartis Pharma Services AG420
终止
3 期
Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)Leukemia, Myeloid, Chronic PhaseNCT00124748Novartis Pharmaceuticals476
终止
1 期
Safety and Tolerability Study of GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis.Colitis, UlcerativeNCT02000453GlaxoSmithKline2